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Abstract: Oxidative stress is an imbalance between the production of free radicals and 
antioxidant defense mechanisms, potentially leading to tissue damage. Oxidative stress has 
a key role in the development of cerebrovascular and/or neurodegenerative diseases.  
This phenomenon is mainly mediated by an enhanced superoxide production by the 
vascular endothelium with its consequent dysfunction. Thioctic, also known as alpha-lipoic 
acid (1,2-dithiolane-3-pentanoic acid), is a naturally occurring antioxidant that neutralizes 
free radicals in the fatty and watery regions of cells. Both the reduced and oxidized forms 
of the compound possess antioxidant ability. Thioctic acid has two optical isomers 
designated as (+)- and (−)-thioctic acid. Naturally occurring thioctic acid is the (+)-thioctic 
acid form, but the synthetic compound largely used in the market for stability reasons is a 
mixture of (+)- and (−)-thioctic acid. The present study was designed to compare the 
antioxidant activity of the two enantiomers versus the racemic form of thioctic acid on 
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hydrogen peroxide-induced apoptosis in a rat pheochromocytoma PC12 cell line. Cell 
viability was evaluated by MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide) assay and free oxygen radical species (ROS) production was assessed by flow 
cytometry. Antioxidant activity of the two enantiomers and the racemic form of thioctic 
acid was also evaluated in spontaneously hypertensive rats (SHR) used as an in vivo model 
of increased oxidative stress. A 3-h exposure of PC12 cells to hydrogen peroxide (H2O2) 
significantly decreased cell viability and increased levels of intracellular ROS production. 
Pre-treatment with racemic thioctic acid or (+)-enantiomer significantly inhibited  
H2O2-induced decrease in cell viability from the concentration of 50 μmol/L and  
20 μmol/L, respectively. Racemic thioctic acid and (+)-salt decreased levels of intracellular 
ROS, which were unaffected by (−)-thioctic acid. In the brain of SHR, the occurrence of 
astrogliosis and neuronal damage, with a decreased expression of neurofilament 200 kDa 
were observed. Treatment of SHR for 30 days with (+)-thioctic acid reduced the size of 
astrocytes and increased the neurofilament immunoreaction. The above findings could 
contribute to clarify the role played by thioctic acid in central nervous system injury related 
to oxidative stress. The more pronounced effect of (+)-thioctic acid observed in this study 
may have practical therapeutic implications worthy of being investigated in further 
preclinical and clinical studies. 
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1. Introduction 
Free radical (e.g., *OH) generation following stroke and traumatic brain injury has been 
documented [1–3]. Reactive oxygen species (ROS) such as *OH can initiate free radical chain 
reactions which can lead to oxidation of cellular constituents and, ultimately, to cell death. The 
occurrence of lipid peroxidation was shown in animal models of both global and focal ischemia [4], in 
which an increase of conjugated dienes and aldehydes derived from oxidized lipids have been  
reported [5,6]. Pentane evolved from lipid peroxidation has been also detected in the expired breath of 
gerbils following global ischemia [7]. 
Free radical involvement in neurodegeneration following stroke is also facilitated by antioxidant 
defenses breakdown. Both ischemic [8] and traumatic [9] central nervous system (CNS) injuries result 
in the loss of α-tocopherol. Decreases in both ascorbic acid and glutathione have been described in 
animal models of CNS injury. Antioxidants of natural and/or synthetic origin were also proposed as 
neuroprotective agents in CNS [10–12].  
Thioctic or alpha-lipoic acid, (1,2-dithiolane-3-pentanoic acid), is a naturally occurring dithiol 
compound synthesized enzymatically in the mitochondrion from octanoic acid. The compound is a 
necessary cofactor for mitochondrial α-ketoacid dehydrogenases, and therefore has a critical role in 
mitochondrial energy metabolism. It is synthesized in the organism and is adsorbed intact from dietary 
sources. After adsorption, it accumulates transiently in many tissues. There is growing evidence that 
orally supplied thioctic acid may not be used as a metabolic cofactor but instead, it elicits a unique set 
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of biochemical activities with potential therapeutic value against different pathophysiologic insults. 
Thioctic acid has been proposed as a potent biological antioxidant and a detoxification agent for 
treating diabetic neuropathy, improving age-associated cardiovascular, cognitive, and neuromuscular 
deficits, and as a modulator of various inflammatory signaling pathways [13]. The pharmacology of 
thioctic acid and its role as a biological antioxidant and neuroprotectant and its function in liver 
metabolism and disease were reviewed [14–17]. 
Due to the presence of an asymmetric carbon C3, thioctic acid exists in two enantiomers, namely 
(+)- and (−)-thioctic acid. Analysis of bacterial and mammalian pyruvate dehydrogenase (PDH) 
complexes has shown that the natural cofactor of the complex is the (+)-enantiomer. Moreover,  
(−)-thioctic acid acts either as a poor substrate or as an inhibitor of (+)-thioctic acid when it interacts 
with 2-oxoacid dehydrogenase multienzyme complexes. Both (+)- and (−)-thioctic acid are reduced 
intracellularly via two enzymatic pathways. (+)-thioctic acid is reduced by dihydrolipoamide 
dehydrogenase (the E3 enzyme in the PDH complex), whereas (−)-thioctic acid is reduced by 
glutathione reductase [18,19].  
An interesting in vitro model of oxidative stress and its pharmacologic treatment is given by PC12 
cells: a rat pheochromocytoma cell line as a model of dopaminergic neurons, which produces 
catecholamines [20]. 
Rat strains with genetically inherited hypertension were developed 50 years ago. The spontaneously 
hypertensive rat (SHR) is probably the model most extensively studied. It has specific and uniform 
genetic predisposition to develop arterial hypertension [21], allowing to study causes, mechanisms, 
pathology and behavioral consequences of the disease. Arterial hypertension also represents an important 
cause of oxidative stress. In fact, it could be considered as a free radical generating source [22] and, 
therefore, SHR can be used as an animal model of oxidative stress. Hypertension-dependent organ 
damage was demonstrated [21,23–25]. These studies clearly evidenced that different organs of SHR 
(e.g., kidney, heart and brain), undergo to hypertension-related ROS-depended damage [26]. Hence, 
SHR may be useful to study the effect of any antioxidant compound.  
This study was designed to investigate the possible neuroprotective effect of thioctic acid and its 
enantiomers both in vitro and in vivo using different techniques such as fluocytometry, 
immunohistochemistry, and morphologic analysis. 
2. Results 
2.1. In Vitro Experiments 
As evaluated by the MTT test, treatment with H2O2 decreased the cell viability of PC12 cells by 
approximately 60%. Pretreatment with (+)-thioctic acid increased cell viability at the 20 µmol/L 
concentration. The same parameter was sensitive to (+/−)-thioctic acid concentrations from 50 to  
100 µmol/L (Figure 1). The ability of thioctic acid to reduce ROS was measured in PC12 cells treated 
with 200 µmol/L H2O2 using DCFDA and flow cytometric analysis. As expected, H2O2 induced a  
twofold increase of DCFDA fluorescence after 3 h. Pre-treatment with 100 µmol/L (+/−)-thioctic acid 
or (+)-thioctic acid for 18 h strongly decreased H2O2-induced DCFDA fluorescence intensity. No 
effects were found using (−)-thioctic acid (Figure 2) or vehicle (data not shown). 
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Figure 1. MTT analysis of PC12 cell viability after different treatments: Vehicle (H2O or 
DMSO), H2O2 (hydrogen peroxide, 200 µmol/L), A ((+/−)-thioctic acid), B ((+)-thioctic 
acid, piperazine salt), C ((+)-thioctic acid, lysine salt), and D ((−)-thioctic acid). The 
Arabic numbers (1, 2, 3 and 4) close to the letters represent the different concentrations 
(100, 50, 20 and 10 µmol/L, respectively) for every treatment. The data were expressed as 
the percentage of viable cells and were the mean of ± SE of three different experiments.  
** p < 0.05 vs. vehicle alone ; * p < 0.05 vs. H2O2 only.  
 
Figure 2. MTT analysis of PC12 cell viability after different treatments: Medium, DCFDA 
(2',7'-dichlorofluorescein diacetate) H2O2 (200 µmol/L), A ((+/−)-thioctic acid),  
B ((+)-thioctic acid, piperazine salt), C ((+)-thioctic acid, lysine salt), and D ((−)-Thioctic 
acid). The Arabic numbers (1, 2, 3 and 4) close to the letters represent the different 
concentrations (100, 50, 20 and 10 µmol/L, respectively) for every treatment. The data 
were expressed as the mean of fluorescence intensity and were the mean of ± SE of three 
different experiments. ** p < 0.05 vs. medium or DCFDA alone; * p < 0.05 vs. H2O2 only. 
 
2.2. In Vivo Experiments 
Body weight values were similar in normotensive WKY or SHR, both in the control or those treated 
with different formulations of thioctic acid. Brain weight values were lower in SHR for both controls 
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and those treated compared to normotensive WKY rats (data not shown). Systolic blood pressure 
values averaged 156 ± 6 mmHg in WKY rats (n = 6) and 209 ± 7 mmHg in control SHR (n = 6,  
p < 0.01 vs. WKY rats). Treatment with any formulation of thioctic acid did not affect significantly 
blood pressure values in SHR (data not shown).  
2.3. Plasma Analysis 
Thiobarbituric acid reactive substances (TBARS) levels increased in the plasma of SHR rats 
compared to WKY rats, thereby indicating an increase of oxidative stress in this animal model  
(Figure 3). Only (+)-thioctic acid treatment decreased the TBARS value significantly.  
Figure 3. TBRAS levels in plasma, expressed as μM of malonyldialdeide, of WKY control 
rats (A), control SHRs (B), SHR treated with (+/−)-thioctic acid 250 μmol/kg/day (C), 
SHR treated with (+/−)-thioctic acid 125 μmol/kg/day (D), SHR treated with (+)-thioctic 
acid 125 μmol/kg/day (E), and SHR treated with (−)-thioctic acid 125 μmol/kg/day (F).  
** p < 0.05 vs. WKY control rats; * p < 0.05 vs. SHR control rats. 
 
2.4. Cerebral Cortex and Hippocampus Immunohistochemistry  
The results of image analysis of frontal cortex and hippocampus are summarized in Table 1. In 
control SHR, a significant increase in the size of glial fibrillary acidic protein (GFAP) immunoreactive 
astrocytes was observed (Table 1, Figures 4 and 5). This phenomenon was more pronounced in the 
CA1 subfield and in dentate gyrus and, to a lesser extent, in the frontal cortex and in the CA3 subfield 
in the order (Table 1). In WKY rats, astrocytes were apparently normal and only few hypertrophic 
elements were observed (Figures 3A and 4A). In SHR, the presence of hypertrophic elements 
characterized by hyper-reactive astrocytes (H/R) and hypertrophic/ hyper-immunoreactive astrocytes 
(H/H) were observed (Figures 4B and 5B). In the frontal cortex, clusters of H/R and H/H elements 
were observed in zone IV near the corpus callosum, where the astrocytes presented a higher number 
and length of cellular processed compared to WKY rats (Figure 4B). In the hippocampus of SHR, 
there was a higher number of H/H elements evident compared to WKY (Figure 5B). Astrocytes 
displayed a marked GFAP immunoreaction in the cell body and an increased number of arborizations. 
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Table 1. Size of GFAP-immunoreactive astrocytes in the frontal cortex and hippocampus 
of the different animal groups investigated. 
 
Frontal Cortex 
Grey matter 
Frontal cortex 
White matter 
Hippocampus 
CA1 subfield 
Hippocampus 
CA3 subfield 
Dentate gyrus 
Mean of immunoreaction areas of astrocytes 
WKY Control 100.2 ± 11.6  75.9 ± 7.8  126.3 ± 16.9 149.9 ± 9.9  102.1 ± 2.8 
SHR Control 129.1 ± 5.1 † 98.8 ± 5.8 † 172.3 ± 9.5 †  145.3 ± 5.7  161.6 ± 11.4 † 
SHR (+/−)  
250 μmol/kg/day 132.4 ± 5.2  83.2 ± 3.3 
‡  153.8 ± 15.9 ‡  153.4 ± 14.1 177.4 ± 4.3  
SHR (+/−)  
125 μmol/kg/day 141.6 ± 11.6  98.5 ± 6.4  210.1 ± 13.4 150.5 ± 12.6 168.4 ± 19.5 
SHR (+)  
125 μmol/kg/day 118.9 ± 9.3 
‡  88.6 ± 5.9 ‡ 130.2 ± 5.9 ‡ 154.6 ± 14.1  173.6 ± 18.4 
SHR (−)  
125 μmol/kg/day 134.1 ± 8.1  130.6 ± 11.6  178.6 ± 12.1  150.1 ± 13.8 175.9 ± 9.7 
Mean of immunoreactions areas of astrocytes is expressed in micron square meter (μm2). Data are mean ± SE; † p < 0.05 
vs. WKY control rats; ‡ p < 0.05 vs. SHR control rats. 
Figure 4. Sections of the frontal cortex (grey matter) processed for the 
immunohistochemical demonstration of glial fibrillary acidic protein (GFAP) in control 
WKY rats (A), control SHRs (B), SHR treated with (+/−)-thioctic acid 125 μmol/kg/day 
(C), SHR treated with (+/−)-thioctic acid 250 μmol/kg/day (D), SHR treated with  
(+)-thioctic acid 125 μmol/kg/day (E), and SHR treated with (−)-thioctic acid  
125 μmol/kg/day (F). Calibration bar: 25 μm. 
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Figure 4. Cont. 
 
Figure 5. Sections of the CA1 subfield (stratum radiatum) processed for the 
immunohistochemical demonstration of glial fibrillary acidic protein (GFAP) in control 
WKY rats (A), control SHRs (B), SHR treated with (+/−)-thioctic acid 125 μmol/kg/day 
(C), SHR treated with (+/−)-thioctic acid 250 μmol/kg/day (D), SHR treated with  
(+)-thioctic acid 125 μmol/kg/day (E), and SHR treated with (−)-thioctic acid  
125 μmol/kg/day (F). Calibration bar: 25 μm. 
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Treatment with (+/−)-thioctic acid (250 μmol/kg/day) (Table 1, Figures 4D and 5D) and, to a 
greater extent, with (+)-thioctic acid (125 μmol/kg/day) (Table 1, Figures 4E and 5E) countered the 
volume increase of GFAP-immunoreactive astrocytes. (−)-Thioctic acid (125 μmol/kg/day) did not 
affect astroglial reaction (Table 1, Figures 3F and 4F). Treatment with (+)-thioctic acid  
(125 μmol/kg/day) (Figures 4E and 5E) but not with (+/−)-thioctic acid at the same concentration  
(Figures 4C and 5C) decreased the number of H/R and H/H elements, both in the frontal cortex and in 
the CA1 subfield. Neurofilament 200 kDa protein (NFP) immunoreactivity was localized in nerve 
fiber-like structures within the frontal cortex (Figure 6) and hippocampus (data not shown). 
Quantitative image analysis revealed in the frontal cortex and, to a lesser extent, in the hippocampus a 
decrease of NFP-immunoreactive structures in SHR, as compared to WKY rats (Figure 6 and Table 2). 
This loss was countered by treatment with (+)-thioctic acid (125 μmol/kg/day) but not by treatment 
with other forms of thioctic acid used (Figure 6 and Table 2). 
Figure 6. Sections of the frontal cortex (Zone 2) processed for the immunohistochemical 
demonstration of neurofilament phosporylated 200 kDa in control WKY rats (A), control 
SHRs (B), SHR treated with (+/−)-thioctic acid 125 μmol/kg/day (C), SHR treated with 
(+/−)-thioctic acid 250 μmol/kg/day (D), SHR treated with (+)-thioctic acid  
125 μmol/kg/day (E), and SHR treated with (−)-thioctic acid 125 μmol/kg/day (F). 
Calibration bar: 25 μm. 
 
Int. J. Mol. Sci. 2013, 14 4588 
 
Table 2. Neurofilament 200 kDa immunoreactivity, in the frontal cortex and hippocampus 
of the different animal groups investigated.  
 
Frontal cortex 
Zone 1 
Frontal cortex 
Zone 2 
Hippocampus 
CA1 subfield 
Hippocampus 
CA3 subfield 
Dentate gyrus 
NFP200 kDa immunoreaction density 
WKY Control 29.2 ± 2.3 45.6 ± 2.1 40.3 ± 2.8 37.4 ± 1.9 41.5 ± 1.3 
SHR Control 15.1 ± 0.4 † 28.84 ± 0.3 † 30.3 ± 1.3 † 36.5 ± 2.3 31.8 ± 1.1 † 
SHR (+/−)  
250 μmol/kg/day 25.8 ± 1.3 
‡ 31.4 ± 0.7 ‡ 35.3 ± 2.1 ‡ 33.5 ± 1.9 36.8 ± 2.1 ‡ 
SHR (+/−)  
125 μmol/kg/day 18.9 ± 0.7 24.1 ± 1.2 29.3 ± 2.1 35.5 ± 2.2 30.8 ± 2.1 
SHR (+)  
125 μmol/kg/day 23.9 ± 1.5 
‡ 39.2 ± 0.8 ‡ 36.3 ± 1.9 ‡ 38.5 ± 2.1 38.2± 2.1 ‡ 
SHR (−)  
125 μmol/kg/day 16.8 ± 1.3 25.9 ±1.2 31.3 ± 2.3 37.5 ± 2.9 29.8 ± 1.7 
Neurofilament immunoreactivity. Values are expressed in arbitrary units calculated microdensitometrically as detailed in 
the materials and methods section. Data are mean ± SE; † p < 0.05 vs. WKY control rats; ‡ p < 0.05 vs. SHR control rats. 
3. Discussion 
Oxidative stress is caused by an imbalance in the redox state of the cell, either by overproduction of 
the reactive oxygen species, or by dysfunction of the antioxidant systems. There are many different 
varieties of partially reduced ROS, including superoxide (O2•−), hydrogen peroxide (H2O2), and the 
hydroxyl radical (OH•). The current use of the term “ROS” includes both oxygen radicals and  
non-radicals that are easily converted into free radicals (O3, H2O2, 1O2) [27]. ROS have different 
degrees of reactivity, the hydroxyl radical OH• being one of the most reactive ROS. Due to their high 
reactive activity, ROS chemically interact with biological molecules, thus leading to changes in cell 
function and, ultimately, cell death. As a result, oxygen has the potential to be poisonous, and aerobic 
organisms can afford this potential damage because of the existence of antioxidant defenses [28]. 
Neurons and astrocytes, are largely responsible for the brain’s massive consumption of O2 and 
glucose. Although brain represents only ~2% of the total body weight, it accounts for more than 20% 
of the total consumption of oxygen [29]. Despite the essentiality of oxygen for living organisms, 
hyperoxia causes toxicity and neurotoxicity of nervous tissue [30]. Oxidative stress has been detected 
in several neurodegenerative diseases, and emerging evidence from in vitro and in vivo disease  
models suggests that oxidative stress may play a role in the pathophysiology of a variety of  
neurological disorders. 
Pathophysiology of arterial hypertension involves complex interactions of multiple vascular effectors, 
including the activation of the sympathetic nervous system, of the renin-angiotensin-aldosterone system, 
and of inflammation mediators. Oxidative stress and endothelial dysfunction are commonly observed 
in hypertensive individuals [31], but increasing evidence suggests that they also have a causal role in 
the molecular processes leading to hypertension. ROS may directly alter vascular function or cause 
changes in vascular tone by several mechanisms, including altered nitric oxide (NO) bioavailability or 
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signaling [31]. ROS-producing enzymes involved in the increased vascular oxidative stress observed 
during hypertension include the NADPH oxidase, xanthine oxidase, the mitochondrial respiratory 
chain and an uncoupled endothelial NO synthase. Hypertension is also considered as a risk factor for 
the development of cognitive dysfunction, for its negative effects on cerebral vasculature and on blood 
flow [32]. In the elderly, it is a major risk factor for vascular cognitive impairment and vascular 
dementia [33–35].  
SHR were developed as an animal model of genetic hypertension and are largely used for 
investigating causes, mechanisms and pathology of hypertension, as well as the influence of 
pharmacological treatments on the development and course of arterial hypertension [21,23,24].  
This genetic model of hypertension exhibits enhanced NAD(P)H oxidase-mediated O2  
generation in resistance arteries (mesenteric), conduit vessels (aorta), and kidneys [26]  
8-Hydroxy-2'-deoxyguanosine, a marker for oxidative stress-induced DNA damage, and protein 
carbonylation, a marker for oxidation status of proteins, are overexpressed in the aorta, heart, and 
kidney of SHR compared to their normotensive cohorts [26]. The enhanced oxidative stress occurring 
in SHR in addition to a brain vascular injury [23] make SHR a reasonable model for investigating the 
potential neuroprotective activity of antioxidant treatment. On the other hand, oxidative stress plays a 
relevant role in ischemia–reperfusion injury [36–38]. Thioctic acid was chosen as an antioxidant as 
increasing evidence indicates neuroprotective activity of the compound in nervous system disorders 
characterized by vascular injury [13,39]. The antioxidant activity of the compound was assigned to the 
(+)-enantiomer [13], although there is no general agreement on it as of yet [40]. 
In our in vitro experiments on PC-12 cell cultures treated with H2O2, only (+)-thioctic acid and 
(+/−)-thioctic acid decreased ROS levels, whereas no effect was observed after treatment with the  
(−)-enantiomer. As demonstrated by MTT assay, the (+)-enantiomer was the most active compound 
able to inhibit the H2O2-induced reduction in cell viability, displaying its effects at a lower 
concentration compared with the other isoform investigated. These findings documenting a higher 
activity of (+)-thioctic acid are consistent with those of a previous study demonstrating a greater 
activity of it [41].  
The goal of the in vivo experiments, was to assess in the model of brain vascular injury represented 
by SHR the influence of treatment with antioxidants on astroglial reaction and on neurofilament 
expression in the primary motor cortex and in a key area for learning and memory, such as 
hippocampus. The findings that the different thioctic acid formulations did not affect blood pressure 
levels in SHR indicate that any activity observed in SHR brain is not related to changes in blood 
pressure. Astrocytes play an active role in maintaining the structure, metabolism and function of the 
brain [42] and become hypertrophic in response to diverse brain injuries. Depending on their activation 
status, they are also referred to as reactive and/or activated astrocytes [43–45]. Reactive astrocytes are 
recognized by their increased size, upregulation of GFAP expression and immunoreactivity [46], and 
that arterial hypertension increases astrocyte activation [23–25]. Oxidative stress likely causes a brain 
suffering status accompanied by increased astrocyte immunoreaction. Treatment with thioctic acid 
decreases the area occupied by glial cells and therefore counters brain injury accompanied by 
increased oxidative stress. These data, similar to those found in another animal model of brain  
injury [47], indicate a more pronounced activity of (+)-thioctic acid compared with (+/−)-thioctic acid, 
whereas (−)-thioctic acid was almost inactive. Similar results were obtained by analysis of 
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cytoskeleton expression. (+)-Thioctic acid was more active in countering cytoskeletal breakdown, 
whereas (+/−)-thioctic acid and (−)-enantiomer were less active or ineffective, respectively. A 
comparative analysis of the results obtained in in vivo experiments with (+)- and with a double dose of 
(+/−)-thioctic acid suggests that the lower activity of the racemic antioxidant is probably due to a 
negative influence of (−)-thioctic acid on the biological activity of the compound.  
Preclinical and clinical studies have suggested that thioctic acid, alone or in association with other 
antioxidant molecules, may represent a neuroprotective agent in cognitive decline [39,48–50]. Our  
in vivo studies showing that systemic administration of thioctic acid has a neuroprotective activity in 
brain areas with a key role in motor and cognitive functions support indirectly the above findings and 
indicate that the compound has a brain tropism. 
In summation, thioctic acid has a neuroprotective effect on microanatomical changes typical of a 
model of brain vascular injury and, therefore, merits further investigations in hypertensive patients 
with brains at risk. Moreover, the more pronounced effect of (+)-thioctic acid demonstrated in this 
study and the lack of activity of (−)-thioctic acid may have practical consequences worth investigating 
in further studies.  
4. Materials and Methods 
4.1. In Vitro Experiments 
4.1.1. Cell Cultures 
Rat pheochromocytoma (PC12) cells (American Type Culture Collection, ATCC, Rockville, MD, 
USA), were maintained in HAM’S-F12 medium with L-glutamine (Lonza, Basel, Switzerland) 
supplemented with 15% heat-inactivated horse serum and 2.5% fetal bovine serum (Lonza),  
100 IU/mL penicillin and 100 mg/mL streptomycin (Lonza) at 37 °C, 5% CO2 and 95% humidity. 
4.1.2. 3-(4,5-Dimethylthiazol-2-yl)-2,5-Diphenyltetrazolium Bromide Assay (MTT) 
Cell viability was measured by MTT. PC12 cells were plated at a density of 1 × 104 cells/well in  
96-well plates and then cultured with different concentrations of (+)-thioctic acid (lysine and 
piperazine salts), (−)-thioctic acid and (+/−)-thioctic acid. Cell cultures were treated for 18 h at 
different concentrations of the above derivatives of thioctic acid (10, 20, 50 and 100 µmol/L) or the 
respective vehicles (DMSO or H2O) and then incubated with 200 µmol/L H2O2 for 3 h. The percentage 
of cytotoxicity was measured by MTT assay. At the end of treatment, MTT was added to the media at 
the final concentration of 0.8 mg/mL and incubated for 3 h. Supernatants were discarded, and colored 
formazan crystals were dissolved with 100 μL of dimethyl sulfoxide (DMSO) and read by an  
enzyme-linked immunoabsorbent assay (ELISA) reader (BioTek Instruments, Winooski, VT, USA). 
Four replicates were used for each treatment. Sample data are represented as the mean ± SD of at least 
three separate experiments. 
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4.1.3. Measurement of ROS Production 
PC12 cells were seeded in 24-well plates at a density of 3 × 105 cells/well. After 24 h, cells were 
pulsed with 10 μg/mL 2',7'-dichlorofluorescein diacetate (DCFDA, Sigma Aldrich, St. Louis, CA, 
USA) for 20 min at 37 °C 5% CO2, treated with (+)-thioctic acid (lysine and piperazine salts),  
(−)-thioctic acid and (+/−)-thioctic acid (10, 20, 50 and 100 µmol/L) or DMSO for 18 h, and then 
incubated with 200 µmol/L H2O2 for 3 h. Cells were then washed with PBS, detached from wells and 
quickly analyzed on a FACScan flow cytometer (Becton Dickinson, San Josè, CA, USA) and the Cell 
Quest software (version 3.1f; Becton Dickinson; San Josè, CA, USA; 1995).  
4.2. In Vivo Experiments  
4.2.1. Animals and Tissue Treatment 
Twenty-week-old male SHR (n = 30) and age-matched WKY rats were treated for 30 days with 
intraperitoneal injection of 250 μmol/kg/day of (+/−)-thioctic acid (n = 6); 125 μmol/kg/day of  
(+/−)-thioctic acid (n = 6); 125 μmol/kg/day of (+)-thioctic acid lysine salt (n = 6) and 25 mM/kg/day 
of (−)-thioctic acid (n = 6).  
Control SHR and WKY rats received the same amounts of vehicle. Rats were handled according to 
internationally accepted principles for care of laboratory animals (European Community Council 
Directive 86/609, O.J. n° L358, 18 December, 1986). Blood pressure values were measured once a 
week by an indirect tail–cuff method in conscious rats. Before killing, animals were anaesthetized with 
pentobarbital sodium (50 mg/kg, i.p.), 5 mL of blood samples were collected by intracardiac 
withdrawal, and then decapitated. In the blood samples, levels of TBARS were measured using 
commercial kits (Cayman Chemical Company, Cat. No. 10009055). The brain was removed from the 
skull, then washed, weighed and divided into the two hemispheres. The left hemisphere was fixed in a 
HistoChoice solution, and embedded in a semi-synthetic paraffin. Serial consecutive 8-μm thick 
sections were stained with Nissl’s method (cresyl violet 1.5%) for morphometric analysis and with 
hematoxylin and eosin for assessing the occurrence of relevant microanatomical changes. The right 
hemisphere was embedded in a cryoprotectant medium and stored at −80 °C until ready for use. Serial 
consecutive 12-μm thick sections were cut using a microtome cryostat and processed for 
immunohistochemistry as detailed below.  
4.2.2. Immunohistochemistry 
Paraffin-embedded coronal sections of the brain (12-µm thick) were processed for the 
immunohistochemical detection of GFAP, and NFP. The 1st, 4th, 7th, 10th, and 13th consecutive 
sections were processed for GFAP immunohistochemistry using a mouse serum against GFAP 
(Chemicon, Millipore, Cat. No. 3402) diluted 1:500 with 0.3% PBS-Triton X 100. The 2nd, 5th, 8th, 
11th and 14th consecutive sections were processed for NFP 200 kDa immunohistochemistry by 
exposing them to a mouse monoclonal antibody raised against NFP 200 kDa (clone RT97, Chemicon, 
Millipore, Cat. No. 5262) diluted 1:500. The 3rd, 6th , 9th, 12th and 15th were used as controls and 
exposed to a non-immune IgG instead of the primary antibody. For immunohistochemistry, sections 
Int. J. Mol. Sci. 2013, 14 4592 
 
were exposed overnight in a moist chamber at 4 °C to primary antibodies and then for 30 min at 25 °C 
to corresponding secondary biotinylated antibodies (mouse-antirabbit IgGs or goat-antimouse IgGs) diluted 
to 1:200. The product of immune reaction was revealed using 3,3'-diaminobenzidine as a chromogen.  
4.2.3. Image Analysis  
Nissl’s stained sections were viewed under a light microscope at a final magnification of ×160. Via 
a TV connection, images were transferred from the microscope to the screen of an IAS 2000 image 
analyzer and used as a microanatomy reference for quantitative immunohistochemistry. The cell body 
area of astrocytes, considered as cells displaying a dark-brown GFAP immunoreactivity, were assessed 
using an overlap function of the IAS 2000 image analyzer. Morphometric data was then analyzed 
according to the protocol described in an earlier paper of our group [51]. The density of 
immunoreaction area occupied by NFP was measured by image analysis in the frontal cortex and 
hippocampus (subfileds CA1, CA3 and dentate gyrus) by protocol detailed elsewhere [52]. The 
intensity of NFP immunostaining developed in the neuropil of the frontal cortex and hippocampus was 
assessed microdensitometrically by calibrating the image analyzer taking as “zero” the background 
developed in sections incubated with a non-immune serum, and “250” as the conventional value of the 
maximum intensity of staining. 
4.2.4. Data Analysis 
Means of different parameters investigated were calculated from single animal data, and group means 
± SEM were then derived from single animal values. The significance of differences between means was 
analyzed by analysis of variance (ANOVA) followed by the Newman–Keuls multiple range test. 
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